ECM
ALLO icon

Evergreen Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Evergreen Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,400
Closed -$242K – 636
2021
Q3 		$242K Hold
9,400
– – 0.01% 492
2021
Q2 		$245K Hold
9,400
– – 0.01% 461
2021
Q1 		$332K Hold
9,400
– – 0.02% 380
2020
Q4 		$237K Hold
9,400
– – 0.01% 384
2020
Q3 		$354K Sell
9,400
-40,236
-81% -$1.52M 0.02% 309
2020
Q2 		$2.13M Buy
+49,636
New +$1.8M 0.16% 130

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Evergreen Capital Management's ALLO Position: Q4 2021 in Review

Evergreen Capital Management sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 9,400 shares — an estimated $242K sold.

Evergreen Capital Management first reported a position in ALLO in Q2 2020 and held it in 6 quarters. The position peaked at $2.13M in Q2 2020. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

  • Evergreen Capital Management reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Evergreen Capital Management sold 9,400 Allogene Therapeutics shares in Q4 2021, an estimated $242K.
  • Evergreen Capital Management first reported a position in Allogene Therapeutics in Q2 2020 and held it in 6 quarters.
  • Evergreen Capital Management's Allogene Therapeutics position peaked at $2.13M in Q2 2020.
  • 177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on Evergreen Capital Management's 13F filing for Q4 2021, filed 11 Mar 2022.